Fed. Circ. Finds Teva Infringed UCB Parkinson's Patch Patent

By Ryan Davis (June 24, 2019, 8:12 PM EDT) -- The Federal Circuit on Monday upheld a lower court's decision that a UCB patent covering Neupro, a patch used to treat Parkinson's disease, is infringed by a planned generic version from a company now owned by Teva, and also that a second patent on the product is invalid.

The three-judge appeals panel found that U.S. District Judge Leonard P. Stark of the District of Delaware reached the correct decisions on both patents following a bench trial in 2017.

The decision leaves intact an injunction barring Actavis Laboratories UT Inc., which was acquired by Teva Pharmaceutical Industries Ltd. in 2016, from selling...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!